

Bronchogenic Carcinoma: Unveiling the Silent Killer

Daisuke Maki*

Department of Radiology, Okayama University Shiga, Shiga, Japan

Introduction

Bronchogenic carcinoma, more commonly known as lung cancer, is a formidable adversary within the realm of oncology. It is a disease that has, for many years, remained a silent killer, gradually infiltrating the lungs and often presenting in its advanced stages, making it one of the leading causes of cancer-related deaths worldwide. In this comprehensive exploration, we will delve into the intricacies of bronchogenic carcinoma, examining its types, causes, risk factors, symptoms, diagnosis, treatment and prevention strategies. Lung cancer is not a single entity but a collective term encompassing various types, primarily categorized into two major groups Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) [1].

Description

NSCLC accounts for approximately 85% of all lung cancer cases. This is the most common form of NSCLC and often occurs in the outer regions of the lung. Adenocarcinomas are more likely to affect non-smokers and are frequently seen in women. Squamous cell carcinoma typically starts in the bronchial tubes' lining. It's strongly associated with smoking and can lead to symptoms like coughing, blood-tinged sputum and chest pain. This is the least common subtype of NSCLC. It typically grows and spreads more rapidly than other NSCLC subtypes. SCLC is less common, accounting for about 15% of lung cancer cases. This type is notorious for its aggressive nature and rapid spread. It often starts in the central airways and is closely linked to smoking. Lung cancer is fundamentally a result of genetic mutations that lead to uncontrolled cell growth in the lungs [2].

Cigarette smoking is the single most significant risk factor for lung cancer, responsible for nearly 85% of all cases. The chemicals in tobacco smoke can damage the DNA in lung cells, leading to cancerous mutations. Even non-smokers exposed to secondhand smoke are at an increased risk of developing lung cancer. Radon is a naturally occurring radioactive gas that can seep into homes through the ground. Prolonged exposure to high levels of radon can increase lung cancer risk. Exposure to asbestos, arsenic, uranium and certain other carcinogens in the workplace can elevate the risk of lung cancer. Prolonged exposure to polluted air, especially in urban areas with high levels of pollutants, can contribute to lung cancer development. A family history of lung cancer may increase the risk, suggesting a possible genetic predisposition. Individuals with a history of lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) are at an increased risk [3].

Lung cancer is often referred to as a "silent killer" because it tends to remain asymptomatic in its early stages. Symptoms may not appear until the disease has progressed significantly. To diagnose lung cancer, various tests and procedures are employed. A common initial screening test that can reveal abnormal masses or nodules in the lungs. A more detailed imaging test that

provides a clearer picture of the lung tissues. The definitive diagnostic test that involves the removal of a tissue sample for examination under a microscope. A procedure in which a thin, flexible tube with a camera is inserted into the airways to inspect and collect samples from the lungs. Positron Emission Tomography (PET) scans can help determine the extent of cancer spread in the body. Treatment for lung cancer depends on the type and stage of the disease, as well as the patient's overall health. Surgical removal of the tumor may be an option for early-stage NSCLC. The extent of the surgery can vary from a segmentectomy (removing a portion of the lung) to a lobectomy (removing an entire lobe of the lung). High-energy radiation is used to target and destroy cancer cells. It can be employed as the main treatment or in conjunction with surgery or chemotherapy. Systemic chemotherapy involves the use of drugs that circulate throughout the body to kill cancer cells. It is typically used for more advanced or widespread cases [4].

Targeted drugs are designed to attack specific mutations or proteins in cancer cells. They are often used in cases of advanced NSCLC. Immunotherapy works by boosting the body's immune system to recognize and attack cancer cells. It has shown promise in treating certain types of lung cancer, particularly NSCLC. In advanced stages of lung cancer, palliative care focuses on improving a patient's quality of life by managing symptoms and providing support. It's important to note that treatment plans are highly individualized and may involve a combination of these modalities. If you smoke, the single most effective way to reduce your lung cancer risk is to quit smoking. It's never too late to stop and the benefits of quitting begin almost immediately. Limit your exposure to secondhand smoke as much as possible. Consider testing your home for radon levels and taking steps to mitigate it if necessary. Follow safety protocols and use protective equipment if you work in an environment with known carcinogens. Maintain a healthy diet, engage in regular physical activity and reduce exposure to environmental pollutants. For individuals at high risk, such as long-term smokers, regular lung cancer screening with low-dose CT scans can help detect cancer at an earlier, more treatable stage [5].

Conclusion

In conclusion, bronchogenic carcinoma, or lung cancer, is a formidable disease that requires comprehensive understanding, effective prevention strategies and advanced treatment options. It remains essential for individuals to be aware of the risks and take proactive steps to protect themselves from this silent killer, which continues to claim countless lives worldwide. By reducing risk factors, promoting early detection and advancing research into innovative treatments, we can hope to make significant strides in the fight against lung cancer, ultimately saving lives and improving the quality of life for those affected by this devastating disease.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Hunninghake, Gary W., David A. Lynch, Jeffrey R. Galvin and Barry H. Gross, et

*Address for Correspondence: Daisuke Maki, Department of Radiology, Okayama University Shiga, Shiga, Japan; E-mail: daisumaki@ybb.ne.jp

Copyright: © 2023 Maki D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 28 June, 2023, Manuscript No. LDT-23-118588; Editor Assigned: 30 June, 2023, PreQC No. P-118588; Reviewed: 12 July, 2023, QC No. Q-118588; Revised: 19 July, 2023, Manuscript No. R-118588; Published: 28 July, 2023, DOI: 10.37421/2472-1018.2023.9.195

- al. "Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia." *Chest* 4 (2003): 1215-1223.
2. Johkoh, Takeshi, Nestor L. Muller, Thomas V. Colby and Kazuya Ichikado, et al. "Nonspecific interstitial pneumonia: Correlation between thin-section CT findings and pathologic subgroups in 55 patients." *Radiology* 225 (2002): 199-204.
 3. Travis, William D., Kazuhiro Matsui, Joel Moss and Victor J. Ferrans. "Idiopathic nonspecific interstitial pneumonia: Prognostic significance of cellular and fibrosing patterns: Survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia." *Am J Surg Pathol* 24 (2000): 19.
 4. Coward, William R., Gauri Saini and Gisli Jenkins. "The pathogenesis of idiopathic pulmonary fibrosis." *Thorax* 65 (2010): 367-388.
 5. Cha, Seung-Ick, Steve D. Groshong, Stephen K. Frankel and Ben L. Edelman, et al. "Compartmentalized expression of c-FLIP in lung tissues of patients with idiopathic pulmonary fibrosis." *Am J Respir Cell Mol Biol* 42 (2010): 140-148.

How to cite this article: Maki, Daisuke. "Bronchogenic Carcinoma: Unveiling the Silent Killer." *J Lung Dis Treat* 9 (2023): 195.